Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway

Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that specifically targets HER2 thanks to its antibody component trastuzumab. In spite of responses to this novel agent, acquired resistance to treatment remains a major obstacle. Prolonged in vitro exposure of the gastroesophageal junction...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauveur, Juliette, Matera, Eva-Laure, Chettab, Kamel, Valet, Philippe, Guitton, Jerome, Savina, Ariel, Dumontet, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940380/
https://www.ncbi.nlm.nih.gov/pubmed/29765526
http://dx.doi.org/10.18632/oncotarget.24975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940380/
https://www.ncbi.nlm.nih.gov/pubmed/29765526
http://dx.doi.org/10.18632/oncotarget.24975

Ejemplares similares